Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma
Early Phase 1
Active, not recruiting
- Conditions
- Smoldering Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2018-08-15
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT03631043
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
Phase 2
Recruiting
- Conditions
- Recurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Drug: Liposome-encapsulated Daunorubicin-CytarabineDrug: Venetoclax
- First Posted Date
- 2018-08-14
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT03629171
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant
Phase 1
Recruiting
- Conditions
- Aplastic AnemiaChronic Myelogenous Leukemia, BCR-ABL1 PositiveMantle Cell LymphomaPlasma Cell MyelomaChronic Lymphocytic LeukemiaMyelodysplastic SyndromeMyeloproliferative NeoplasmBone Marrow FailureFollicular LymphomaHodgkin Lymphoma
- Interventions
- Biological: Anti-Thymocyte GlobulinDrug: CyclophosphamideBiological: Cytokine-treated Veto CellsDrug: FludarabineProcedure: Peripheral Blood Stem Cell TransplantationRadiation: Total-Body Irradiation
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03622788
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
Phase 2
Active, not recruiting
- Conditions
- Recurrent Plasma Cell Myeloma
- Interventions
- Biological: Daratumumab
- First Posted Date
- 2018-08-09
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 13
- Registration Number
- NCT03622775
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
M7824 in Treating Patients With Stage II-III HER2 Positive Breast Cancer
Phase 1
Completed
- Conditions
- Anatomic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIB Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage IIA Breast Cancer AJCC v8Anatomic Stage IIIC Breast Cancer AJCC v8Prognostic Stage III Breast Cancer AJCC v8Prognostic Stage IIA Breast Cancer AJCC v8Prognostic Stage IIIA Breast Cancer AJCC v8Prognostic Stage IIIC Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8
- Interventions
- First Posted Date
- 2018-08-08
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT03620201
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Manual Therapy in Treating Fibrosis-Related Late Effect Dysphagia in Head and Neck Cancer Survivors
Not Applicable
Active, not recruiting
- Conditions
- Cancer SurvivorHead and Neck CarcinomaDysphagiaFibrosis
- Interventions
- Procedure: Manual Therapy
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03612531
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
Phase 2
Terminated
- Conditions
- Platinum-Resistant Ovarian CarcinomaRecurrent High Grade Ovarian Serous AdenocarcinomaRefractory Colorectal CarcinomaMalignant Solid NeoplasmMetastatic Colorectal AdenocarcinomaMetastatic Pancreatic Ductal AdenocarcinomaStage IV Colorectal Cancer AJCC v8Stage IVC Colorectal Cancer AJCC v8Metastatic Ovarian CarcinomaRecurrent Ovarian Carcinosarcoma
- Interventions
- Biological: Autologous Tumor Infiltrating Lymphocytes MDA-TILDrug: CyclophosphamideDrug: FludarabineBiological: Interleukin-2Other: Quality-of-Life Assessment
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT03610490
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
IExosomes in Treating Participants with Metastatic Pancreas Cancer with KrasG12D Mutation
Phase 1
Active, not recruiting
- Conditions
- KRAS NP_004976.2:p.G12DMetastatic Pancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaStage IV Pancreatic Cancer AJCC V8
- Interventions
- Drug: Mesenchymal Stromal Cells-derived Exosomes with KRAS G12D siRNA
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2024-10-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT03608631
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Navigated Repetitive Transcranial Magnetic Stimulation in Improving Motor Rehabilitation in Participants With Brain Tumors
Not Applicable
Active, not recruiting
- Conditions
- Brain Neoplasm
- Interventions
- Other: Questionnaire AdministrationProcedure: Transcranial Magnetic Stimulation
- First Posted Date
- 2018-07-30
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT03606161
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Phase 1
Recruiting
- Conditions
- Primary Peritoneal CarcinomaBreast CarcinomaFallopian Tube CarcinomaOvarian CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Fallopian Tube CarcinomaSolid NeoplasmRecurrent Ovarian Carcinoma
- Interventions
- Procedure: Computed TomographyRadiation: Fludeoxyglucose F-18Radiation: Fluorine F 18 FluorthanatraceProcedure: Positron Emission Tomography
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 300
- Registration Number
- NCT03604315
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath